^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Lymphoma

Related cancers:
24h
Golidocitinib Combined With GemOx in RR PTCL (clinicaltrials.gov)
P2, N=31, Not yet recruiting, Ruijin Hospital
New P2 trial
|
oxaliplatin • golidocitinib (DZD4205)
24h
New P1 trial
|
doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • daunorubicin • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
24h
Undetectable IgE is associated with non-infectious complications of common variable immune deficiency. (PubMed, Ann Allergy Asthma Immunol)
Undetectable IgE is a readily available biomarker that in a patient with CVID may direct clinicians to be particularly vigilant for non-infectious complications of CVID.
Journal
|
CD4 (CD4 Molecule)
24h
Prevention of cholestatic liver disease through BCL6-FXR enterohepatic crosstalk. (PubMed, Cell Mol Gastroenterol Hepatol)
Remarkably, combined ablation caused almost complete loss of hepatic Shp expression, upregulation of the rate-limiting BA synthesis enzyme CYP7A1, severe elevation in BA levels, and cholestatic liver damage. Together, these findings reveal BCL6 as a key modulator of FXR enterohepatic signaling to maintain BA homeostasis and protect the liver from cholestatic injury.
Journal
|
BCL6 (B-cell CLL/lymphoma 6) • FGFR4 (Fibroblast growth factor receptor 4)
24h
Protective effect of obeticholic acid on cyclophosphamide-induced thyroid toxicity in rats by inhibiting TXNIP/NLRP3/ASC/caspase-1-dependent pyroptosis and p53/BAX/caspase-3-dependent apoptosis. (PubMed, Biomed Pharmacother)
Mechanistically, OCA suppressed inflammation via downregulation of TLR4/MYD88/NF-κB signalling, inhibited pyroptosis through TXNIP/NLRP3/ASC/caspase-1 pathway blockade and reduced p53-mediated apoptosis by modulating BAX, BCL-2 and cleaved caspase-3 expression. This study provides the first evidence that OCA confers protection against CYC-induced thyroid injury by reducing oxidative stress, inflammation, pyroptosis and apoptosis.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • IL18 (Interleukin 18) • TLR4 (Toll Like Receptor 4) • NLRP3 (NLR Family Pyrin Domain Containing 3) • TXNIP (Thioredoxin Interacting Protein) • CASP1 (Caspase 1)
|
cyclophosphamide
24h
Primary Rosai-Dorfman disease of lung and mediastinum: A clinicopathological and immunohistochemical study of five cases. (PubMed, Pathol Res Pract)
RDD of the lung and mediastinum is rare, with a wide range of ages. Histologically, there are often lymphoid follicles with germinal centers and interstitial fibrosis or sclerosis. This together with the expression of BCL2 and CD30 in the histiocytes can lead to misdiagnosis of lymphomas or other lymphoproliferative diseases or missed diagnosis, particularly in the mediastinum. Careful histological examination for the diagnostic feature of emperipolesis together with characteristic Cyclin D1, OCT2, S100 protein, and CD68 positivity are important clues for accurate diagnosis.
Journal • IO biomarker
|
ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CCND1 (Cyclin D1) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
|
TNFRSF8 expression
24h
Quercetin mitigated LPS-induced PANoptosis in the bursa of Fabricius via the cGAS/STING signaling pathway in broilers. (PubMed, Poult Sci)
This study confirms that QUE exerts a protective effect against LPS-induced PANoptosis via cGAS/STING pathway in the broiler bursa of Fabricius, thereby providing a novel theoretical basis for the application of QUE as a green feed additive. Notably, this finding underscores the potential of QUE as a natural and effective alternative to traditional antibiotics in animal feed, which is of great significance for reducing antibiotic dependence and facilitating the sustainable development of the poultry farming industry.
Journal
|
STING (stimulator of interferon response cGAMP interactor 1) • CGAS (Cyclic GMP-AMP Synthase)
2d
CD22 Redirected Autologous T Cells for ALL (clinicaltrials.gov)
P1, N=41, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting
Enrollment closed
|
CD22 (CD22 Molecule)
2d
Identification and functional characterization of splicing factors implicated in mantle cell lymphoma aggressiveness. (PubMed, Sci Rep)
Survival analyses revealed that co-high expression of SRSF1, HNRNPF, or PTBP1 and oncogenic MYC predicts poor clinical outcomes in MCL patients. Our data describe the clinical significance of aberrant SRSF1, hnRNP F, and PTBP1 in MCL and their tumor-promoting roles via the regulation of cancer hallmarks, which could be important in understanding MCL pathogenesis and therapeutic development.
Journal
|
CASP3 (Caspase 3) • PTBP1 (Polypyrimidine Tract Binding Protein 1)
2d
Primary Cutaneous CD30-Positive Lymphoproliferative Disorder With Gamma-Delta T-Cells: A Molecular-Annotated Case With a Classic Clinical Appearance and Behavior. (PubMed, J Cutan Pathol)
Altogether, these findings were insufficient to establish a diagnosis of pcGDTCL. We review the clinical, histopathologic, and molecular sequencing data pertaining to our rare patient as well as the recent literature on indolent CD30+LPD with gamma-delta T-cells.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • TNFRSF8 (TNF Receptor Superfamily Member 8) • LRP1B (LDL Receptor Related Protein 1B) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • EPHA7 (EPH Receptor A7)
|
HER-2 mutation • TNFRSF8 positive
2d
Pembrolizumab in Neoplasms or Lymphomas (clinicaltrials.gov)
P2, N=18, Suspended, Dana-Farber Cancer Institute | Trial completion date: Aug 2025 --> Mar 2026
Trial completion date
|
Keytruda (pembrolizumab)
2d
Nodal T-follicular helper cell lymphoma with hodgkin/reed-sternberg-like cells: Clinicopathologic and molecular characterization of 11 cases. (PubMed, Pathol Res Pract)
AITL with HRS-like cells is prone to misdiagnosis as CHL due to overlapping morphological and immunophenotypic features. Integration of EBER, TCR/IG clonality assessment, and molecular profiling, particularly the identification of TET2 and RHOA mutations is essential for accurate classification. Recognizing this entity is critical for avoiding diagnostic pitfalls and guiding appropriate therapeutic strategies.
Journal • PD(L)-1 Biomarker • IO biomarker
|
DNMT3A (DNA methyltransferase 1) • PD-1 (Programmed cell death 1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • BCL6 (B-cell CLL/lymphoma 6) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • CREBBP (CREB binding protein) • PAX5 (Paired Box 5) • CD4 (CD4 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • ICOS (Inducible T Cell Costimulator) • RHOA (Ras homolog family member A) • MME (Membrane Metalloendopeptidase) • BRD4 (Bromodomain Containing 4)
|
TET2 mutation • TNFRSF8 positive • TNFRSF8 expression
|
CART-30